Literature DB >> 22564797

Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.

Glenn Wagner1, Karen Chan Osilla, Jeffrey Garnett, Bonnie Ghosh-Dastidar, Laveeza Bhatti, Mallory Witt, Matthew Bidwell Goetz.   

Abstract

Despite low uptake of hepatitis C virus (HCV) treatment among HIV co-infected patients, few studies have examined the factors that contribute to provider decisions to recommend treatment. Surveys of 173 co-infected patients and their primary care providers, as well as patient chart data, were collected at 3 HIV clinics in Los Angeles; 73% of the patients had any history of being recommended HCV treatment. Multivariate predictors of being offered treatment included being Caucasian, greater HCV knowledge, receiving depression treatment if depressed, and one's provider having a lower weekly patient load and more years working at the study site. These findings suggest that provider decisions to recommend HCV treatment are influenced by patient factors including race and psychosocial treatment readiness, as well as characteristics of their own practice and treatment philosophy. With changes to HCV treatment soon to emerge, further evaluation of factors influencing treatment decisions is needed to improve HCV treatment uptake.

Entities:  

Mesh:

Year:  2012        PMID: 22564797      PMCID: PMC3419326          DOI: 10.1177/1545109712444163

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  39 in total

Review 1.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002).

Authors: 
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

2.  Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals.

Authors:  Lynn E Taylor; Theresa Costello; Elizabeth Alt; Gail Yates; Karen Tashima
Journal:  AIDS       Date:  2002-08-16       Impact factor: 4.177

3.  Treatment of hepatitis C infection in injection drug users.

Authors:  M Backmund; K Meyer; M Von Zielonka; D Eichenlaub
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

4.  Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection.

Authors:  Shawn L Fultz; Amy C Justice; Adeel A Butt; Linda Rabeneck; Sharon Weissman; Maria Rodriguez-Barradas
Journal:  Clin Infect Dis       Date:  2003-04-01       Impact factor: 9.079

5.  The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

Authors:  V Di Martino; P Rufat; N Boyer; P Renard; F Degos; M Martinot-Peignoux; S Matheron; V Le Moing; F Vachon; C Degott; D Valla; P Marcellin
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

6.  Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.

Authors:  Karen Chan Osilla; Glenn Wagner; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Mallory Witt; Laveeza Bhatti; Matthew Bidwell Goetz
Journal:  AIDS Patient Care STDS       Date:  2011-08-08       Impact factor: 5.078

7.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

Authors:  I Bica; B McGovern; R Dhar; D Stone; K McGowan; R Scheib; D R Snydman
Journal:  Clin Infect Dis       Date:  2001-01-23       Impact factor: 9.079

8.  Treating hepatitis C in methadone maintenance patients: an interim analysis.

Authors:  Diana L Sylvestre
Journal:  Drug Alcohol Depend       Date:  2002-07-01       Impact factor: 4.492

9.  Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.

Authors:  Catherine A Fleming; Donald E Craven; David Thornton; Sheila Tumilty; David Nunes
Journal:  Clin Infect Dis       Date:  2002-12-11       Impact factor: 9.079

10.  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.

Authors:  Martin Schaefer; Folkhard Schmidt; Christian Folwaczny; Reinhard Lorenz; Gaby Martin; Norbert Schindlbeck; Walter Heldwein; Michael Soyka; Heinz Grunze; August Koenig; Klaus Loeschke
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

View more
  3 in total

1.  Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients.

Authors:  Glenn Wagner; Karen Chan Osilla; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Laveeza Bhatti; Matthew Bidwell Goetz; Mallory Witt
Journal:  AIDS Res Treat       Date:  2011-10-26

Review 2.  Conceptual framework for outcomes research studies of hepatitis C: an analytical review.

Authors:  Urbano Sbarigia; Tom R Denee; Norris G Turner; George J Wan; Alan Morrison; Anna S Kaufman; Gary Rice; Geoffrey M Dusheiko
Journal:  Infect Drug Resist       Date:  2016-05-27       Impact factor: 4.003

Review 3.  State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization.

Authors:  Cecilia Trucchi; Andrea Orsi; Cristiano Alicino; Laura Sticchi; Giancarlo Icardi; Filippo Ansaldi
Journal:  J Immunol Res       Date:  2016-10-24       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.